Key result
TandemHeart PVAD support in 25 patients with hemodynamic compromise yielded a 30-day survival rate of 56% and significantly improved mixed venous oxygen saturation (P=0.008).
Population
25 heterogeneous patients requiring percutaneous ventricular assist device support.
Design
Case_series
Follow-up
>90 days
Authors
Loading...
May support short-term stabilization in severe compromise; leaves open bridge-to-recovery role pending controlled trials.
Observational (n=25)
No
The TandemHeart percutaneous ventricular assist device provides favorable hemodynamic support and serves as a viable bridge-to-recovery or bridge-to-device for heterogeneous patients with severe hemodynamic compromise, though vascular access complications are common.
Tempelhof et al. (2011) conducted an observational in Hemodynamic compromise requiring PVAD support (n=25). TandemHeart percutaneous ventricular assist device was evaluated on 30-day survival. TandemHeart PVAD support in 25 patients with hemodynamic compromise yielded a 30-day survival rate of 56% and significantly improved mixed venous oxygen saturation (P=0.008).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: